Labcorp Holdings (LSE:0JSY) - Prezzo delle azioni, notizie e analisi

0JSY Panoramica delle azioni

Labcorp Holdings Inc. fornisce servizi di laboratorio. Maggiori dettagli

0JSY analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	2/6

Premi

Negoziato a 67.7% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 20.56% all'anno

Analisi del rischio

Ha un alto livello di debito

Grandi elementi una tantum che incidono sui risultati finanziari

Labcorp Holdings Inc. Concorrenti

Integrated Diagnostics Holdings

LSE:IDHC

US$229.9m

Smith & Nephew

LSE:SN.

UK£8.6b

Mediclinic International

LSE:MDC

UK£3.7b

ConvaTec Group

LSE:CTEC

UK£4.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Labcorp Holdings
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$239.82
Massimo di 52 settimane	US$248.07
Minimo di 52 settimane	US$192.43
Beta	1.04
1Variazione di 1 mese	4.75%
Variazione a 3 mesi	3.42%
Variazione di 1 anno	12.96%
3Variazione a 3 anni	-17.73%
Variazione a 5 anni	38.47%
Variazione dall'IPO	35.94%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	0JSY	GB Healthcare	GB Mercato
7D	2.7%	0.6%	2.2%
1Y	13.0%	-22.6%	8.0%

Ritorno vs Industria: 0JSY ha superato il UK Healthcare che ha restituito -22.6 % nell'ultimo anno.

Rendimento vs Mercato: 0JSY ha superato il mercato UK che ha restituito 8 % nell'ultimo anno.

Volatilità dei prezzi

Is 0JSY's price volatile compared to industry and market?
0JSY volatility
0JSY Average Weekly Movement	2.9%
Healthcare Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Prezzo delle azioni stabile: 0JSY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di 0JSY è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1995	61,975	Adam Schechter	www.labcorp.com

Labcorp Holdings Inc. fornisce servizi di laboratorio. Opera attraverso due segmenti, Diagnostics Laboratories e Biopharma Laboratory Services. L'azienda offre vari test, come analisi chimiche del sangue, analisi delle urine, emocromo, tiroide, PAP, emoglobina A1C e vitamina D, antigeni specifici della prostata, malattie a trasmissione sessuale, epatite C, colture e procedure microbiologiche, test per l'abuso di alcol e altre sostanze.

Labcorp Holdings Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Labcorp Holdings con la sua capitalizzazione di mercato?
0JSY statistiche fondamentali
Capitalizzazione di mercato	US$20.05b
Guadagni(TTM)	US$435.50m
Ricavi(TTM)	US$12.71b

46.0x

Rapporto P/E

1.6x

Rapporto P/S

0JSY è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
0JSY Conto economico (TTM)
Ricavi	US$12.71b
Costo del fatturato	US$9.16b
Profitto lordo	US$3.55b
Altre spese	US$3.11b
Guadagni	US$435.50m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	5.21
Margine lordo	27.92%
Margine di profitto netto	3.43%
Rapporto debito/patrimonio netto	83.2%

Come si è comportato 0JSY nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.2%

Rendimento attuale del dividendo

56%

Rapporto di remunerazione

0JSY paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di 0JSY

Quando è necessario acquistare 0JSY per ricevere un dividendo imminente?
Labcorp Holdings date dei dividendi
Data di stacco del dividendo	Nov 26 2024
Data di pagamento dei dividendi	Dec 13 2024
Giorni fino al dividendo Ex	2 days
Giorni prima della data di pagamento dei dividendi	19 days

0JSY paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di 0JSY

0JSY Panoramica delle azioni

Premi

Analisi del rischio

Labcorp Holdings Inc. Concorrenti

LSE:IDHC

US$229.9m

LSE:SN.

UK£8.6b

LSE:MDC

UK£3.7b

LSE:CTEC

UK£4.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Upcoming dividend of US$0.72 per share

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Recent updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Upcoming dividend of US$0.72 per share

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold US$3.4m worth of stock

Insider recently sold US$2.8m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023)

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Upcoming dividend of US$0.72 per share

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.35 in 1Q 2023)

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

CFO & Executive VP recently sold US$4.4m worth of stock

Upcoming dividend of US$0.72 per share

Full year 2023 earnings released: EPS: US$4.35 (vs US$14.04 in FY 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.91 in 3Q 2022)

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold US$1.1m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus